Evidence map›Paper›PMID 28735972›Full record

ReviewComparative biochemistry and physiology. Part B, Biochemistry & molecular biology2017

Pyrimidine metabolism in schistosomes: A comparison with other parasites and the search for potential chemotherapeutic targets.

Mahmoud H El Kouni

Abstract readReview
In one paragraph

Review in Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 35 citations in OpenAlex.

  1. TargetingFrontiers in microbiology · 2026
    Review
  2. Schistosomiasis trends and control efforts: a global perspective from 1990 to 2050.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Proteomic analysis ofFrontiers in veterinary science · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mahmoud H El KouniDepartment of Pharmacology and Toxicology, Center for AIDS Research, Comprehensive Cancer Center, General Clinical Research Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: melkouni@uab.edu.
University of Alabama at Birmingham · US

Funding

Toxoplasma Adenosine Kinase &ChemotherapyR01AI052838 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI EL KOUNI, MAHMOUD H · 2004 to 2007
$2.0M
ADENOSINE KINASE TARGET FOR CHEMOTHERAPY IN TGONDIIR01AI042975 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI EL KOUNI, MAHMOUD H · 1997 to 2001
$475k
PURINE ANALOGUE METABOLISM IN TOXOPLASMA GONDILR01AI029848 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI EL KOUNI, MAHMOUD H · 1990 to 1994
–
ADENOSINE KINASE TARGET FOR CHEMOTHERAPY IN T GONDIIR21AI039950 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI EL KOUNI, MAHMOUD H · 1996 to 1996
–
NIAID NIH HHS R01 AI022219NIAID NIH HHS R01 AI029848NIAID NIH HHS R01 AI042975NIAID NIH HHS R01 AI052838NIAID NIH HHS R21 AI039950
6 · The paper itself

Abstract

Schistosomes are responsible for the parasitic disease schistosomiasis, an acute and chronic parasitic ailment that affects >240 million people in 70 countries worldwide. It is the second most devastating parasitic disease after malaria. At least 200,000 deaths per year are associated with the disease. In the absence of the availability of vaccines, chemotherapy is the main stay for combating schistosomiasis. The antischistosomal arsenal is currently limited to a single drug, Praziquantel, which is quite effective with a single-day treatment and virtually no host-toxicity. Recently, however, the question of reduced activity of Praziquantel has been raised. Therefore, the search for alternative antischistosomal drugs merits the study of new approaches of chemotherapy. The rational design of a drug is usually based on biochemical and physiological differences between pathogens and host. Pyrimidine metabolism is an excellent target for such studies. Schistosomes, unlike most of the host tissues, require a very active pyrimidine metabolism for the synthesis of DNA and RNA. This is essential for the production of the enormous numbers of eggs deposited daily by the parasite to which the granulomas response precipitates the pathogenesis of schistosomiasis. Furthermore, there are sufficient differences between corresponding enzymes of pyrimidine metabolism from the host and the parasite that can be exploited to design specific inhibitors or "subversive substrates" for the parasitic enzymes. Specificities of pyrimidine transport also diverge significantly between parasites and their mammalian host. This review deals with studies on pyrimidine metabolism in schistosomes and highlights the unique characteristic of this metabolism that could constitute excellent potential targets for the design of safe and effective antischistosomal drugs. In addition, pyrimidine metabolism in schistosomes is compared with that in other parasites where studies on pyrimidine metabolism have been more elaborate, in the hope of providing leads on how to identify likely chemotherapeutic targets which have not been looked at in schistosomes.

Indexed as

AnimalsPraziquantelPyrimidinesSchistosomaSchistosomiasisSchistosomicidesPraziquantelpyrimidinePyrimidinesSchistosomicidesChemotherapyEnzymesParasitesPyrimidineSchistosomesTransport

Identifiers

PMID28735972
PMCPMC5593796
OpenAlexW2738618300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.